Item 2.02 Results of Operations and Financial Condition. On August 13, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and six months ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures.…
Filed Aug 13, 2026Accepted Aug 13, 2026, 9:00 AM EDTCIK 1858685Accession 0001493152-26-037610
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
August 13, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results
for the three and six months ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this
Current Report on Form 8-K.
The
Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of
a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded
or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting
principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
The
information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference
in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
EX-99.1
2
ex99-1.htm
EX-99.1
Exhibit 99.1
Biofrontera
Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
WOBURN,
Mass., August 13, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical
company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial
results for the quarter ended June 30, 2026.
Second
Quarter 2026 Highlights
Net
product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year
period.
Gross
margin of 80%, compared to 71% in the prior-year period, an improvement of approximately
920 basis points, reflecting the lower Ameluz® cost structure established following the
closing of the strategic transaction with Biofrontera AG in October 2025 (the “Strategic
Transaction”).
Net
loss of $0.6 million, or $(0.05) per share, compared to a net loss of $5.3 million, or $(0.57)
per share, in the prior-year period.
Adjusted
EBITDA of $(0.2) million, compared to $(5.1) million in the prior-year period, an improvement
of approximately $5.0 million.
First
Half 2026 Highlights
…